ATWLPPR Peptide TFA, a heptapeptide, acts as a selective neuropilin-1 inhibitor, inhibits VEGF 165 binding to NRP-1, used in the research of angiogenesis. ATWLPPR Peptide TFA has potential in reducing the early retinal damage caused by diabetes . Appearance:Solid IC50& Target:Neuropilin-1 In Vitro:ATWLPPR Peptide TFA is a selective neuropilin-1 inhibitor, inhibits VEGF 165 binding to NRP-1 by 82% at 100 μM. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo:ATWLPPR (400 μg/kg, s.c.) preserves vascular integrity and decreases the oxidative stress level, possibly reduces the early retinal damage caused by diabetes. ATWLPPR prevents the increase of inflammation-associated proteins (GFAP, VEGF and ICAM-1) i Biological Activity:ATWLPPR Peptide TFA, a heptapeptide, acts as a selective neuropilin-1 inhibitor, inhibits VEGF 165 binding to NRP-1, used in the research of angiogenesis. ATWLPPR Peptide TFA has potential in reducing the early retinal damage caused by diabetes.
All
Chemical Reagents
Biomedicine
Organic raw materials
Inorganic chemical industry
intermediate
Agricultural chemicals
Auxiliaries and catalysts
Fragrances and Flavors
Dyes and Pigments
Daily chemical industry
ATWLPPR Peptide TFA
CAS number：unknown molecular formula：
overview
compound introduction
Specs
| Chinese alias | - | ||
| English alias | - | ||
| CAS number | unknown | molecular formula | |
| molecular weight | - | Exact mass | ≥99% |
| PSA | - | logp | - |
numbering system
No numbering system information yet
physicochemical properties
No physical and chemical property information yet
Safety information
No safety information yet
Production methods and uses
No production method and use information yet
Related
upstream information
No upstream information yet
downstream information
No downstream information yet
MSDS
Found 0 shareMSDS
